216 related articles for article (PubMed ID: 12041671)
21. [Leukemic transformation of polycythemia vera after treatment with hydroxyurea and chromosome 17 abnormalities].
Tóthová E; Nebesnáková E; Kafková A; Stecová N; Fricová M
Vnitr Lek; 1999 Aug; 45(8):487-9. PubMed ID: 11045151
[TBL] [Abstract][Full Text] [Related]
22. Treatment of polycythemia vera with hydroxyurea.
Donovan PB; Kaplan ME; Goldberg JD; Tatarsky I; Najean Y; Silberstein EB; Knospe WH; Laszlo J; Mack K; Berk PD
Am J Hematol; 1984; 17(4):329-34. PubMed ID: 6496458
[TBL] [Abstract][Full Text] [Related]
23. Polycythemia vera and hydroxyurea resistance/intolerance: a monocentric retrospective analysis.
Demuynck T; Verhoef G; Delforge M; Vandenberghe P; Devos T
Ann Hematol; 2019 Jun; 98(6):1421-1426. PubMed ID: 30919072
[TBL] [Abstract][Full Text] [Related]
24. Cytogenetic abnormalities and leukemic transformation in hydroxyurea-treated patients with Philadelphia chromosome negative chronic myeloproliferative disease.
Löfvenberg E; Nordenson I; Wahlin A
Cancer Genet Cytogenet; 1990 Oct; 49(1):57-67. PubMed ID: 2397474
[TBL] [Abstract][Full Text] [Related]
25. Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia.
Teofili L; Giona F; Martini M; Cenci T; Guidi F; Torti L; Palumbo G; Amendola A; Foà R; Larocca LM
J Clin Oncol; 2007 Mar; 25(9):1048-53. PubMed ID: 17369568
[TBL] [Abstract][Full Text] [Related]
26. Leukemic transformation in myeloproliferative neoplasms: therapy-related or unrelated?
Björkholm M; Hultcrantz M; Derolf ÅR
Best Pract Res Clin Haematol; 2014 Jun; 27(2):141-53. PubMed ID: 25189725
[TBL] [Abstract][Full Text] [Related]
27. New drugs in essential thrombocythemia and polycythemia vera.
Tefferi A; Elliott MA; Solberg LA; Silverstein MN
Blood Rev; 1997 Mar; 11(1):1-7. PubMed ID: 9218101
[TBL] [Abstract][Full Text] [Related]
28. Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
Duangnapasatit B; Rattarittamrong E; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Tantiworawit A; Norasetthada L
Asian Pac J Cancer Prev; 2015; 16(12):5013-8. PubMed ID: 26163633
[TBL] [Abstract][Full Text] [Related]
29. Leg ulcers in elderly on hydroxyurea: a single center experience in Ph- myeloproliferative disorders and review of literature.
Ruzzon E; Randi ML; Tezza F; Luzzatto G; Scandellari R; Fabris F
Aging Clin Exp Res; 2006 Jun; 18(3):187-90. PubMed ID: 16804363
[TBL] [Abstract][Full Text] [Related]
30. Anagrelide: analysis of long-term efficacy, safety and leukemogenic potential in myeloproliferative disorders.
Fruchtman SM; Petitt RM; Gilbert HS; Fiddler G; Lyne A;
Leuk Res; 2005 May; 29(5):481-91. PubMed ID: 15755500
[TBL] [Abstract][Full Text] [Related]
31. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion.
Sterkers Y; Preudhomme C; Laï JL; Demory JL; Caulier MT; Wattel E; Bordessoule D; Bauters F; Fenaux P
Blood; 1998 Jan; 91(2):616-22. PubMed ID: 9427717
[TBL] [Abstract][Full Text] [Related]
32. Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol; 2013 Jun; 88(6):507-16. PubMed ID: 23695894
[TBL] [Abstract][Full Text] [Related]
33. Leukemic transformation in polycythemia vera: analysis of risk factors.
Nand S; Messmore H; Fisher SG; Bird ML; Schulz W; Fisher RI
Am J Hematol; 1990 May; 34(1):32-6. PubMed ID: 2327402
[TBL] [Abstract][Full Text] [Related]
34. Leukemic transformation of polycythemia vera after treatment with hydroxyurea with abnormalities of chromosome 17.
Tóthová E; Fricová M; Stecová N; Hlebasková M; Kafková A; Raffac S; Guman T; Svorcová E; Nebesnáková E
Neoplasma; 2001; 48(5):389-92. PubMed ID: 11845984
[TBL] [Abstract][Full Text] [Related]
35. Diagnosis and treatment of thrombocythemia in myeloproliferative disorders.
Gilbert HS
Oncology (Williston Park); 2001 Aug; 15(8):989-96, 998; discussion 999-1000,1006,1008. PubMed ID: 11548978
[TBL] [Abstract][Full Text] [Related]
36. Comparative genomic hybridization in polycythemia vera and essential thrombocytosis patients.
Herishanu Y; Lishner M; Bomstein Y; Kitay-Cohen Y; Fejgin MD; Gaber E; Amiel A
Cancer Genet Cytogenet; 2001 Jul; 128(2):154-7. PubMed ID: 11463455
[TBL] [Abstract][Full Text] [Related]
37. Leukemic transformation in three patients with polycythemia vera. Analysis of the clinicopathological features and N-ras gene mutation.
Sakai H; Karasawa M; Okamoto K; Maehara T; Tsukamoto N; Murakami H; Naruse T; Morita K; Tsuchiya J
J Med; 1996; 27(3-4):183-91. PubMed ID: 8982966
[TBL] [Abstract][Full Text] [Related]
38. Polycythemia vera and essential thrombocythemia in young patients.
Frezzato M; Ruggeri M; Castaman G; Rodeghiero F
Haematologica; 1993; 78(6 Suppl 2):11-7. PubMed ID: 8039752
[TBL] [Abstract][Full Text] [Related]
39. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
Bellucci S; Michiels JJ
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
[TBL] [Abstract][Full Text] [Related]
40. Prediction of thrombotic and hemorrhagic events during polycythemia vera or essential thrombocythemia based on leukocyte burden.
Lim Y; Lee JO; Kim SH; Kim JW; Kim YJ; Lee KW; Lee JS; Bang SM
Thromb Res; 2015 May; 135(5):846-51. PubMed ID: 25743883
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
